Kura Oncology (KURA) Lifted to Hold at Zacks Investment Research
Kura Oncology (NASDAQ:KURA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
A number of other research analysts have also recently issued reports on the company. BidaskClub raised Kura Oncology from a “hold” rating to a “buy” rating in a report on Wednesday, January 24th. Wedbush assumed coverage on Kura Oncology in a report on Tuesday, December 26th. They issued a “buy” rating and a $19.00 price target for the company. Oppenheimer set a $18.00 price target on Kura Oncology and gave the company a “buy” rating in a report on Monday, December 11th. Cann reissued a “buy” rating and set a $17.50 price objective on shares of Kura Oncology in a report on Monday, December 11th. Finally, ValuEngine cut Kura Oncology from a “hold” rating to a “sell” rating in a report on Friday, December 1st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $18.08.
Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Tuesday, November 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.01). equities analysts predict that Kura Oncology will post -1.52 EPS for the current fiscal year.
Large investors have recently made changes to their positions in the business. Rhumbline Advisers bought a new stake in Kura Oncology during the 2nd quarter worth about $131,000. New York State Common Retirement Fund bought a new stake in Kura Oncology during the 2nd quarter worth about $142,000. OxFORD Asset Management LLP bought a new stake in Kura Oncology during the 2nd quarter worth about $217,000. Schwab Charles Investment Management Inc. bought a new stake in Kura Oncology during the 2nd quarter worth about $226,000. Finally, California State Teachers Retirement System bought a new stake in Kura Oncology during the 2nd quarter worth about $235,000. 62.96% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This report was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.dailypolitical.com/2018/02/08/kura-oncology-kura-lifted-to-hold-at-zacks-investment-research.html.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.